Skip to main content
Top
Published in: Supportive Care in Cancer 7/2018

Open Access 01-07-2018 | Original Article

Management and survival analysis of elderly patients with a cancer in the digestive system who refused to receive anticancer treatments

Authors: Jun Wan, Shiping Xu, Yinqiao Wu, Benyan Wu, Dezhong Joshua Liao, Ningzhi Xu, Gangshi Wang

Published in: Supportive Care in Cancer | Issue 7/2018

Login to get access

Abstract

Treatment and management of cancers in elderly patients require some special considerations. A better understanding of how cancers progress in those elderly patients who have not received any anticancer treatments could better help us in treating these patients and in making end-of-life decisions. Over the past years, we had encountered 57 elderly patients, aged 75 to 94 years (87.6 on average), with a cancer in the digestive system, who refused to accept anticancer treatment but who did receive the best available supportive and palliative care. Clinicopathological data of these patients were analyzed. Of these 57 cases, 49 were at an advanced or late stage, while the remaining eight were at an early stage at the time of diagnosis. The median overall survival time of all the patients was 11 months, and almost the entire cohort manifested multiple-organ impairments. The average number of malfunctioning organs per patient was 3.68. After carefully predicting, and then preventing or managing complications, only 54.4% of the patients eventually died of multiple-organ functional failure. Nearly 18% of the single organ dysfunctions were finally well-controlled. Our data provide the first statistical information on the survival time and the direct cause of death of the elderly patients with a cancer in the digestive system not treated with chemotherapy or other direct anticancer interventions, but who did receive the best available supportive and palliative cares. During their struggle with cancer, elderly patients clearly could benefit from prophylactic interventions on organ dysfunction.
Literature
2.
go back to reference Tavares A, Gandra A, Viveiros F, Cidade C, Maciel J (2013) Analysis of clinicopathologic characteristics and prognosis of gastric cancer in young and older patients. Pathol Oncol Res 19:111–117CrossRefPubMed Tavares A, Gandra A, Viveiros F, Cidade C, Maciel J (2013) Analysis of clinicopathologic characteristics and prognosis of gastric cancer in young and older patients. Pathol Oncol Res 19:111–117CrossRefPubMed
4.
go back to reference Steinhauser KE, Christakis NA, Clipp EC, McNeilly M, McIntyre L, Tulsky JA (2000) Factors considered important at the end of life by patients, family, physicians, and other care providers. JAMA 284:2476–2482CrossRefPubMed Steinhauser KE, Christakis NA, Clipp EC, McNeilly M, McIntyre L, Tulsky JA (2000) Factors considered important at the end of life by patients, family, physicians, and other care providers. JAMA 284:2476–2482CrossRefPubMed
5.
go back to reference Zhang B, Nilsson ME, Prigerson HG (2012) Factors important to patients’ quality of life at the end of life. Arch Intern Med 172:1133–1142PubMedPubMedCentral Zhang B, Nilsson ME, Prigerson HG (2012) Factors important to patients’ quality of life at the end of life. Arch Intern Med 172:1133–1142PubMedPubMedCentral
6.
go back to reference Zimmermann C, Burman D, Swami N, Krzyzanowska MK, Leighl N, Moore M, Rodin G, Tannock I (2011) Determinants of quality of life in patients with advanced cancer. Support Care Cancer 19:621–629CrossRefPubMed Zimmermann C, Burman D, Swami N, Krzyzanowska MK, Leighl N, Moore M, Rodin G, Tannock I (2011) Determinants of quality of life in patients with advanced cancer. Support Care Cancer 19:621–629CrossRefPubMed
7.
go back to reference Edge SB C.C.F.A.G.F.T.A (2010) AJCC cancer staging manual. Edge SB CCFAGFTA, ed. New York, Springer Edge SB C.C.F.A.G.F.T.A (2010) AJCC cancer staging manual. Edge SB CCFAGFTA, ed. New York, Springer
9.
go back to reference Maffei S, Colantoni A, Kaleci S, Benatti P, Tesini E, de Leon MP (2016) Clinical features of colorectal cancer patients in advanced age: a population-based approach. Intern Emerg Med 11:191–197CrossRefPubMed Maffei S, Colantoni A, Kaleci S, Benatti P, Tesini E, de Leon MP (2016) Clinical features of colorectal cancer patients in advanced age: a population-based approach. Intern Emerg Med 11:191–197CrossRefPubMed
13.
go back to reference Wright AA, Keating NL, Ayanian JZ, Chrischilles EA, Kahn KL, Ritchie CS, Weeks JC, Earle CC, Landrum MB (2016) Family perspectives on aggressive cancer care near the end of life. JAMA 315:284–292CrossRefPubMedPubMedCentral Wright AA, Keating NL, Ayanian JZ, Chrischilles EA, Kahn KL, Ritchie CS, Weeks JC, Earle CC, Landrum MB (2016) Family perspectives on aggressive cancer care near the end of life. JAMA 315:284–292CrossRefPubMedPubMedCentral
14.
go back to reference Smith TJ, Temin S, Alesi ER, Abernethy AP, Balboni TA, Basch EM, Ferrell BR, Loscalzo M, Meier DE, Paice JA, Peppercorn JM, Somerfield M, Stovall E, von Roenn JH (2012) American Society of Clinical Oncology provisional clinical opinion: the integration of palliative care into standard oncology care. J Clin Oncol 30(8):880–887. https://doi.org/10.1200/JCO.2011.38.5161 CrossRefPubMed Smith TJ, Temin S, Alesi ER, Abernethy AP, Balboni TA, Basch EM, Ferrell BR, Loscalzo M, Meier DE, Paice JA, Peppercorn JM, Somerfield M, Stovall E, von Roenn JH (2012) American Society of Clinical Oncology provisional clinical opinion: the integration of palliative care into standard oncology care. J Clin Oncol 30(8):880–887. https://​doi.​org/​10.​1200/​JCO.​2011.​38.​5161 CrossRefPubMed
15.
go back to reference Hammel P, Huguet F, van Laethem JL, Goldstein D, Glimelius B, Artru P, Borbath I, Bouche O, Shannon J, Andre T et al (2016) Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib: the LAP07 randomized clinical trial. JAMA 315(17):1844–1853. https://doi.org/10.1001/jama.2016.4324 CrossRefPubMed Hammel P, Huguet F, van Laethem JL, Goldstein D, Glimelius B, Artru P, Borbath I, Bouche O, Shannon J, Andre T et al (2016) Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib: the LAP07 randomized clinical trial. JAMA 315(17):1844–1853. https://​doi.​org/​10.​1001/​jama.​2016.​4324 CrossRefPubMed
16.
go back to reference Karve S, Lorenzo M, Liepa AM, Hess LM, Kaye JA, Calingaert B (2015) Treatment patterns, costs, and survival among medicare-enrolled elderly patients diagnosed with advanced stage gastric cancer: analysis of a linked population-based cancer registry and administrative claims database. J Gastric Cancer 15:87–104CrossRefPubMedPubMedCentral Karve S, Lorenzo M, Liepa AM, Hess LM, Kaye JA, Calingaert B (2015) Treatment patterns, costs, and survival among medicare-enrolled elderly patients diagnosed with advanced stage gastric cancer: analysis of a linked population-based cancer registry and administrative claims database. J Gastric Cancer 15:87–104CrossRefPubMedPubMedCentral
18.
go back to reference Patel SS, Nelson R, Sanchez J, Lee W, Uyeno L, Garcia-Aguilar J, Hurria A, Kim J (2013) Elderly patients with colon cancer have unique tumor characteristics and poor survival. Cancer 119:739–747CrossRefPubMed Patel SS, Nelson R, Sanchez J, Lee W, Uyeno L, Garcia-Aguilar J, Hurria A, Kim J (2013) Elderly patients with colon cancer have unique tumor characteristics and poor survival. Cancer 119:739–747CrossRefPubMed
19.
go back to reference Shah MA, Janjigian YY, Stoller R, Shibata S, Kemeny M, Krishnamurthi S, Su YB, Ocean A, Capanu M, Mehrotra B, Ritch P, Henderson C, Kelsen DP (2015) Randomized multicenter phase II study of modified docetaxel, cisplatin, and fluorouracil (DCF) versus DCF plus growth factor support in patients with metastatic gastric adenocarcinoma: a study of the US gastric cancer consortium. J Clin Oncol 33(33):3874–3879. https://doi.org/10.1200/JCO.2015.60.7465 CrossRefPubMed Shah MA, Janjigian YY, Stoller R, Shibata S, Kemeny M, Krishnamurthi S, Su YB, Ocean A, Capanu M, Mehrotra B, Ritch P, Henderson C, Kelsen DP (2015) Randomized multicenter phase II study of modified docetaxel, cisplatin, and fluorouracil (DCF) versus DCF plus growth factor support in patients with metastatic gastric adenocarcinoma: a study of the US gastric cancer consortium. J Clin Oncol 33(33):3874–3879. https://​doi.​org/​10.​1200/​JCO.​2015.​60.​7465 CrossRefPubMed
20.
go back to reference van Steenbergen LN, Lemmens VE, Rutten HJ, Wymenga AN, Nortier JW, Janssen-Heijnen ML (2012) Increased adjuvant treatment and improved survival in elderly stage III colon cancer patients in The Netherlands. Ann Oncol 23:2805–2811CrossRefPubMed van Steenbergen LN, Lemmens VE, Rutten HJ, Wymenga AN, Nortier JW, Janssen-Heijnen ML (2012) Increased adjuvant treatment and improved survival in elderly stage III colon cancer patients in The Netherlands. Ann Oncol 23:2805–2811CrossRefPubMed
21.
go back to reference Ruiz-Tovar J, Martin-Perez E, Fernandez-Contreras ME, Reguero-Callejas ME, Gamallo-Amat C (2010) Impact of preoperative levels of hemoglobin and albumin on the survival of pancreatic carcinoma. Rev Esp Enferm Dig 102:631–636PubMed Ruiz-Tovar J, Martin-Perez E, Fernandez-Contreras ME, Reguero-Callejas ME, Gamallo-Amat C (2010) Impact of preoperative levels of hemoglobin and albumin on the survival of pancreatic carcinoma. Rev Esp Enferm Dig 102:631–636PubMed
25.
go back to reference Nakata B, Amano R, Kimura K, Hirakawa K (2013) Comparison of prognosis between patients of pancreatic head cancer with and without obstructive jaundice at diagnosis. Int J Surg 11:344–349CrossRefPubMed Nakata B, Amano R, Kimura K, Hirakawa K (2013) Comparison of prognosis between patients of pancreatic head cancer with and without obstructive jaundice at diagnosis. Int J Surg 11:344–349CrossRefPubMed
Metadata
Title
Management and survival analysis of elderly patients with a cancer in the digestive system who refused to receive anticancer treatments
Authors
Jun Wan
Shiping Xu
Yinqiao Wu
Benyan Wu
Dezhong Joshua Liao
Ningzhi Xu
Gangshi Wang
Publication date
01-07-2018
Publisher
Springer Berlin Heidelberg
Published in
Supportive Care in Cancer / Issue 7/2018
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-018-4065-9

Other articles of this Issue 7/2018

Supportive Care in Cancer 7/2018 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine